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Abstract. It has been hypothesized that polymorphisms of interleukin (IL)-10 genes affect the risk of developing late onset
Alzheimer’s disease (AD). However, results of different studies are often inconsistent. Our aim was to investigate by meta-
analysis the association of the common polymorphisms comprehensively defining the genetic variability of the IL-10 gene with
AD risk. Fifteen studies investigating the association between IL-10 polymorphisms (-1082, -819, -592) and AD were found and
analyzed. The model-free approach was applied to meta-analyze these case-control genetic association studies. Available data
suggested an association between -1082 polymorphism and AD risk with a marginal statistical significance (GG versus AG/AA:
pooled odds ratio [OR]: 0.82, 95% confidence interval CI: 0.65–1.02) and evidence of a moderate degree of between-study
heterogeneity (χ2 = 27.13, d.f. = 13, p = 0.01, I2 = 52%). For the -819 and -592 polymorphisms, we did not find an association
with AD, but significant between-study heterogeneity made genotype data pooling unacceptable. Analysis by IL-10 haplotype
showed that the -1082G/-819C/-592C haplotype is associated with a lower risk of AD, although with a marginal statistical
significance, probably due to the low number of studies included (GCC versus other genotypes: OR: 0.61, 95% CI: 0.32–1.15;
I2: 85%). Current findings suggest a possible association between -1082 A > G polymorphism and the risk of developing AD;
this effect is more evident in the oldest patients. The high degree of between-study heterogeneity, due to several underpowered
studies and to other methodological problems of individual studies underlies the need for further methodologically adequate
studies.
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INTRODUCTION
Inflammation of the brain is a prominent patho-
logical feature of Alzheimer’s disease (AD) [1, 2].
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sita` di Palermo, Corso Tukory, 211, 90134 Palermo, Italy.
Tel.: +39 0916555911; Fax: +39 091 23860793; E-mail:
calogero.caruso@unipa.it.
The inflammatory response includes activation of
microglia, astrocytes, and the complement system,
as well as increased cytokine expression and acute
phase proteins [2–4]. A number of polymorphisms
in cytokine genes associated with inflammation have
been investigated in AD, both coding for pro-
inflammatory cytokines, such as interleukin (IL)-1,
IL-1, IL-6, and tumor necrosis factor (TNF)- genes
and for anti-inflammatory cytokines, such as IL-10.
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These polymorphisms influence the production of
cytokines and were shown to be correlated with dif-
ferent risk of AD in several studies [2–7].
The IL-10 gene, which maps on chromosome 1 (q31-
q32), is one of the main anti-inflammatory cytokines
[8]. Three polymorphic areas are documented within
the IL-10 gene cluster (-1082G/A, -819 T/C, -592C/A),
which constitute three different haplotypes by various
reciprocal combinations, namely GCC, ACC, ATA,
which were thought to be associated respectively with
high, intermediate, and low IL-10 production [9, 10].
The genetic association between IL-10 and AD has
been investigated several times. The initial studies
reported an association between low producing IL-10
genotypes and the risk of AD [11, 12], but subsequent
studies did not confirm the initial observations. The
inconsistency between the results of different studies
seems to be mainly due to the heterogeneity of the
populations under study and the small sample size
of most studies, resulting in little statistical power
[11–25].
A recent meta-analysis on the association between
the IL-10 -1082 single nucleotide polymorphism
(SNP) and the risk of AD showed that subjects with the
low producing genotypes are at higher risk of develop-
ing AD [7]. However the results of this meta-analysis
were hampered by some mistakes in reporting the
genotype frequencies. In this study, we updated the pre-
vious meta-analysis with recently published studies,
and corrected the incorrect frequencies. We also pooled
the results of all available population-based studies
of the association between the other IL-10 SNPs
(-819 and -592) and AD, to ascertain whether there
is a genetic effect of IL-10 on AD susceptibility.
METHODS
Selection of studies
The primary source of the studies addressing the
role of IL-10 polymorphisms in AD was the PUBMED
database (from January 2003 to August 2011) lim-
ited to English language literature, and the selection of
the search of the specific polymorphism (IL-10 -1082;
IL-10 -819, IL-10 -592) for the search on the Alz-
Gene database. The medical subject headings used for
the PUBMED searches were “interleukin-10”, “poly-
morphisms”, and “Alzheimer’s disease”. The abstracts
found were read to identify studies examining the
genotype association between IL-10 SNP, and AD.
We also performed a manual search of references
cited in published articles. The studies were read in
their entirety to assess their appropriateness for inclu-
sion in the meta-analysis. Criteria for the inclusion in
the analysis were: diagnosis of Alzheimer’s disease
according to the Diagnostic and Statistical Manual
of Mental Disorders (DSM), and the National Insti-
tute of Neurological Disorders and Stroke-Alzheimer
Diseases and Related Disorders (NINCDS-ADRDA)
working group criteria [26], case-control studies, avail-
able genotypes.
Data extraction
Extraction of the data was independently per-
formed by two readers (DDB and CC) who compared
results and agreed on a consensus; disagreements were
resolved by discussion.
Statistical analysis
To analyze our data, we used Review Manager, ver-
sion 5.1, a statistical software package for managing
and analyzing all aspects of a Cochrane Collaboration
systematic review (Oxford, England: The Cochrane
Collaboration, 1999). The overall odds ratio (OR)
among the frequencies of genotypes in both cases and
controls was estimated with models based on both
fixed effects and random effects assumptions. The
fixed effects model considers only within-study vari-
ability. The random effects model uses weights that
incorporate both the within-study and between-study
variance. Because of the high heterogeneity between
the populations of most of the studies included in this
meta-analysis, we have presented the results of random
effects models that are the most conservative ones [27].
The 95% confidence interval (95% CI) of the OR was
also calculated as well as heterogeneity that was quan-
tified by the I2 statistics [28]. Moreover, we excluded
each study in turn, to ensure that no single study would
be solely responsible for the significance of any result
(so-called robust analysis). Influential analysis—that
is, the exclusion of outlying studies until homogeneity
has been achieved—was also used to explore hetero-
geneity. This method was used to examine the effect
of studies identified as being aberrant in either results
or conduct.
Power estimates were calculated with PS software,
v. 2.1.43 [29]. Briefly, power was estimated using the
number of case and controls, and the prevalence of the
putative susceptibility allele or genotype in the control
population.
The putative risk genotype in homozygosity
(-1082 GG, putatively protecting from AD; -819 CC;
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-592 CC), was compared to the other two aggregated
genotype data (-1082 AG+AA; -819 CT+TT; -592
AC+AA), condensing the results into one statistic.
This allowed us to highlight the effect of the puta-
tive risk/protecting genotype, as well as maintaining
the statistical power compared to separately analyzing
all possible transmission models which would have
led to a loss of observation and, thus, of statistical
power. Before aggregating data from genotypes, we
ensured that there were no differences between these
two subgroups.
As previously stated, the IL-10 -1082 polymorphism
was also analyzed by Zhang and colleagues in a recent
meta-analysis [7]. In the Zhang study, the two putative
low producing genotypes (AA+AG analyzed collec-
tively) were compared to the high producing genotype
(GG), aiming to show a higher AD risk for subjects
with the IL-10 low producing AA+AG genotypes. In
our study, the complementary outcome was evaluated,
that is the reduction of risk of developing AD in sub-
jects with the putative IL-10 high producing genotype.
Subgroup analysis was used to explore and to
explain the diversity in the results of different stud-
ies. We used as stratifying variables: 1) the statistical
power of a study to detect an OR of 1.25 (at a signif-
icance level of 0.05), the average allelic OR reported
for all the associative genetic studies on AD [30]; 2)
ethnicity; 3) gender; 4) mean age of AD patients, 5)
criteria used to determine AD diagnosis (clinical or
confirmed neuropathologically or by imaging); and 6)
Mini Mental State Examination (MMSE) in control
population.
RESULTS
Characteristics of the included studies
Fifteen case-control studies of the association
between IL-10 SNP and AD were identified by our
search strategy [11–25]. The main features of the stud-
ies included in the meta-analyses are shown in Table 1.
All studies had case-control design including a total of
2,708 patients and 2,948 healthy controls. The percent-
age of AD female patients was reported in 13 out of
15 studies and ranged from 42% to 78%; the Cousin
study [23] did not report the gender of the enrolled
population, while the Giedraitis study [21] included
only male patients. The median age of AD patients
was 76, ranging from 64.9 ± 7.8 (The Cousin study
[23], including not only early onset AD) to 82.2, but it
was not reported in one study [18]. The sample size of
the studies varied greatly, ranging from 19 to 488, as
well as the number of controls, ranging from 20 to 475.
Neuropathological examination was performed in one
out of 15 studies [19]. Imaging (magnetic resonance
imaging/computerized tomography, MRI/CT) exami-
nation of the brain to support the clinical diagnosis
(MRI/CT) was performed in only three studies [12,
22, 25]. In 9 out of 15 studies, healthy controls were
selected by Mini-Mental Status Examination (MMSE)
[12, 14–18, 20, 21, 25]. All studies were performed on
Caucasian populations, except the study of Nishimura
[16], conducted in Japan; the study of Ma [17], con-
ducted in China; the Vural study [22], conducted in
Turkey; and the Ramos study [18], conducted in the
Table 1
Characteristics of the populations included in the meta-analysis of IL-10 polymorphisms (-1082, -819, -592) and AD
Study Country AD Healthy controls
n Female (%) Age (years) NC MRI/CT n Age Male (%) MMSE
Lio [11] Italy 132 65 68.9∗ No No 213 − 38 No
Depboylu [13] Germany 406 42 70.2 ± 10 No No 251 66.8 ± 10.6 38 No
Infante [14] Spain 232 67 72.1 ± 8.1 No No 191 79.9 ± 7.5 71 Yes
Scassellati [15] Italy 215 − 80.3 ± 8.6 No No 153 71.2 ± 8 − Yes
Arosio [12] Italy 65 68 80 ± 2 No Yes 65 82 ± 2 62 Yes
Nishimura [16] Japan 172 60 77.4 ± 9.7 No No 163 75.5 ± 9.9 61 Yes
Ma [17] China 95 78 77.6 ± 5.8 No No 117 73 ± 6.8 75 Yes
Ramos [18] U.S.A. 265 62 − No No 347 − 63 Yes
Culpan [19] France 160 65 81.2 ± 7.3 Yes No 92 79.7 ± 7.5 49 No
Bagnoli [20] Italy 222 60 69.4 ± 7.8∗ No No 179 72.9 ± 24 70 Yes
Giedraitis [21] Sweden 86 0 82.2∗ No No 404 81.8 0 Yes
Vural [22] Turkey 101 65 76.2 ± 6.8 No Yes 138 73.1 ± 6.9 67 No
Cousin [23] U.K. 488 − 64.9 ± 9.9 No No 475 66.2 ± 10.8 − No
Shawkatova [24] Slovakia 50 53 77.3∗ No No 140 73.1 11 No
Ribizzi [25] Italy 19 73.3 76.3 No Yes 20 73.1 80 Yes
Overall 2708 Overall 2948
∗Age of onset. NC: neuropathological diagnosis. CT: Computerized tomography. MRI: Magnetic Resonance Imaging. MMSE: Mini Mental
State Examination.
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USA, enrolling different ethnicities from the Seattle
area.
Meta-analysis: IL-10 -1082 SNP
Fourteen out of 15 studies were available for
the inclusion in the meta-analysis of the association
between the -1082 SNP and AD. The genotype effects
for GG versus AG/AA genotypes were estimated for
each of these studies (Fig. 1A). Eleven studies showed
an reduced risk of developing AD in subjects with GG
genotype compared to AG or AA genotypes [11–13,
15, 17–19, 21–24], but only three of them achieved
statistical significance [11, 12, 22]. The pooled sum-
mary OR was 0.82 (GG versus AG/AA: OR: 0.82,
95% CI: 0.65–1.02; p = 0.07) with a marginal sta-
tistical significance using the random-effects model,
suggesting that subjects with the high producing IL-10
genotype (GG) have a marginal lower risk of develop-
ing AD. There was evidence of heterogeneity between
the results of individual studies (GG versus AG/AA:
χ2 = 27.13, d.f. = 13, p = 0.01, I2 = 52%).
After exclusion of the Ma study [17], the one
conducted in Asian population, we performed an influ-
ential analysis among studies enrolling population
with similar ethnicity, which identified the study from
Ribizzi [25] as the influential study. The I2 value
for heterogeneity excluding this study decreased from
52% to 43% with a similar effect size (OR, −0.80;
95% CI, −0.65 to −0.99), but statistically significant
(p < 0.004).
To reduce heterogeneity and to evaluate whether
there was a different genotype effect in predefined sub-
groups of studies, we performed subgroup analysis in
relation to patient (age, gender) and study characteris-
tics (type of AD diagnosis, MMSE in controls, sample
Fig. 1. A) Meta-analysis of 14 case-control studies of the IL-10 -1082 polymorphism and risk of AD using the random-effects model. B) Subgroup
analysis, including studies with clinical diagnosis confirmed by MRI/CT or neuropathologic examination, on IL-10 -1082 polymorphism and
risk of Alzheimer’s disease (AD) using the random-effects model. The odds ratio and 95% confidence interval (CI) for the effect of the GG
genotype on AD are plotted on the graph. Studies are arranged chronologically based on the year of publication. HC, healthy controls.
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size and statistical power of individual studies). Anal-
yses by mean age of AD patients (below/above the
median value of 76), showed that when the analysis
included studies enrolling patients with a median age
above 76 [12, 15, 17, 19, 21, 24], the GG genotype was
associated with a statistically significant reduced risk
of AD compared to AA and AG genotypes (OR, –0.72;
95% CI, −0.58 to −0.91). (The Ribizzi study [25]
was excluded as the influential study, and the Ramos
study [18] was excluded since the mean age was not
reported). When we analyzed only the studies in which
the clinical diagnosis was supported by MRI/CT [12,
21, 22] together with the only retrospective study per-
formed on neuropathologically confirmed AD patients
[19], we observed a remarkable reduction in the risk
of AD in subjects with the GG genotype, (OR, −0.59;
95% CI, −0.37 to −0.93; p: 0.002; I2 = 43%) (Fig. 1B).
Analyses by 1) mean age of healthy controls
(below/above the median value of 73.1), 2) percent-
age of female AD patients enrolled (below/above the
median value of 63.5), 3) studies with/without healthy
controls selected by MMSE, and 4) statistical power
of individual studies (below/above the median value of
0.14) did not show any difference in the overall effect
(data not shown).
Meta-analysis: IL-10 -819 SNP
The effect of the IL-10 -819 CC genotype on the
risk of AD is shown in Fig. 2. Five out of 9 studies
[11–13, 20, 24] showed a reduced AD risk in patients
with the CC genotype compared to the other genotypes,
but only two of them achieved statistical significance
[11, 20], without evidence of significant summary OR
(OR = 0.91; 95% C.I.: 0.60–1.37; p = 0.65). A remark-
able between-study heterogeneity was reported (χ2
41.18; df 8; p < 0.00001; I2 = 81%). Influence analysis
showed a reduction of heterogeneity (from I2 = 81% to
52%) in Caucasian studies after exclusion of the studies
of Scassellati [15], Ribizzi [25], and Culpan [19] with
a different and statistically significant pooled estimate
(OR −0.57; 95% CI, −0.42 to −0.77; p < 0.0003).
Subgroup analyses using the same study characteris-
tics for -1082 SNP did not show any change in overall
OR.
Meta-analysis: IL-10 -592 SNP
The effect of the IL-10 -592 CC genotype on the
risk of AD is shown in Fig. 3. Four out of 9 studies
[11–13, 24] showed an increased AD risk in patients
with the CC genotype compared to other genotypes, but
only one achieved statistical significance [11], with-
out evidence of significant summary OR (OR = 0.96;
95% C.I.: 0.70–1.30; p = 0.65). There was evidence
of high between-study heterogeneity (χ2 26.79; df
8; p < 0.0008; I2 = 70%). Influence analysis showed a
reduction of heterogeneity (from I2 = 70% to 22%) in
Caucasian studies after exclusion of the Lio study [11]
with a similar pooled estimate (OR 1.02; 95% CI, 0.82
to 1.26). Subgroup analyses using the same study char-
acteristics for -1082 SNP did not show any change in
overall OR.
Meta-analysis IL-10 GCC genotype
In four out of 15 studies, the role of IL-10 haplotype
was analyzed. The -1082G/-819C/-592C haplotype
Fig. 2. Meta-analysis of 9 case-control studies of the IL-10 -819 polymorphism and risk of Alzheimer’s disease (AD) using the random-effects
model. The odds ratio and 95% confidence interval (CI) for the effect of the GG genotype on AD are plotted on the graph. Studies are arranged
chronologically based on the year of publication. HC, healthy controls.
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Fig. 3. Meta-analysis of 9 case-control studies of the IL-10 -592 polymorphism and risk of Alzheimer’s disease (AD) using the random-effects
model. The odds ratio and 95% confidence interval (CI) for the effect of the CC genotype on AD are plotted on the graph. Studies are arranged
chronologically based on the year of publication. HC, healthy controls.
(GCC haplotype) is the most prevalent one and was
associated with the highest IL-10 levels. The effect of
the IL-10 GCC haplotype on the risk of AD is shown in
Fig. 4. Three out of four studies [11, 20, 24] showed a
statistically significant reduction of AD risk in patients
with the GCC haplotype compared to other haplotypes.
Only the Scassellati study [15] did not show an advan-
tage of the GCC haplotype compared to the others.
The pooling estimate showed a clear reduction of
the risk of developing AD in subjects with the GCC
genotype (OR = 0.61; 95% C.I.: 0.32–1.15), but with
a marginal statistical significance and high degree of
heterogeneity (χ2 20; df 3; p < 0.0002; I2 = 85%).
DISCUSSION
Our meta-analysis summarized the evidence to date
regarding the association between common polymor-
phisms that comprehensively capture the variability of
IL-10 gene and the risk of AD. The available evidence
is not sufficient to draw strong conclusions regarding a
role of the three IL-10 SNPs that have been investigated
to date in AD. The results indicate a possible associa-
tion between the IL-10 -1082 SNP and AD, while no
association was revealed for the other two IL-10 SNPs
analyzed.
Our results contrast with those of a recent meta-
analysis on the role of IL-10 -1082 SNP in AD,
showing a significant association between AA+AG
genotypes with the risk of AD. In the Zhang meta-
analysis [7] and in ours, the same outcome was
analyzed, but the results were expressed as comple-
mentary data; the increased AD risk in subjects with the
AA+AG genotypes in the Zhang study and the reduced
risk of AD in our study. The reason for the discrepancy
between the results of the meta-analyses stem from the
fact that the authors [7] include the study of Combar-
ros [31], instead of the study by Infante [14], which we
included in our analysis. The populations of healthy
controls included in these two studies from the same
Fig. 4. Meta-analysis of 4 case-control studies of the IL-10 -1082G/-819C/-592C haplotype and risk of Alzheimer’s disease (AD) using the
random-effects model. The odds ratio and 95% confidence interval (CI) for the effect of the CC genotype on AD are plotted on the graph. Studies
are arranged chronologically based on the year of publication. HC, healthy controls.
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working group is almost completely overlapping, but
the genotype frequencies of cases are different, lead-
ing to opposite conclusions from these two studies.
We included the original study by Infante [14], since it
seems in the Combarros study [31] that the same con-
trol population as the Infante study was used (historical
control). Another reason explaining the inconsistency
between our conclusions and those of the Zhang study
[7] is related to some mistakes in reporting genotype
frequencies observed in this study.
Significant heterogeneity exists between the results
of individual studies. Because several potential sources
of heterogeneity are present in this set of data, several
steps were considered in the investigation of the causes.
Influential analysis, in which one study is excluded
at a time, was performed to ascertain the impact of
removing each of the studies on between-study hetero-
geneity. This analysis identified the study by Ribizzi
[25] as largely responsible for the heterogeneity of
results of the -1082 SNP meta-analysis. This study
was conducted on a very small sample size, only 19
patients, and showed very little statistical power, not
sufficient to prevent misleading conclusions. Remov-
ing this study from the overall analysis reduced the
degree of heterogeneity and led to a statistically sig-
nificant association between the high IL-10 producing
genotype GG in homozygosity and reduced risk of AD.
A similar procedure was performed for the -819
meta-analysis. In this case, 3 out of 9 studies were
removed until heterogeneity was reduced to acceptable
levels. Removing these studies [15, 19, 25] from the
analysis showed a statistically significant association
between the putative high IL-10 producing CC geno-
type and reduced risk of AD. However, in this case we
were unable to define an overarching pattern of vari-
ables to differentiate the outlying samples from the
rest of the data set, at least considering the aggregated
data commonly present in the single studies (mean age,
gender distribution, ethnicity, sample size, type of AD
diagnosis, etc.).
Although all the studies investigated late-onset AD,
the age range varied largely between studies, ranging
from 64.9 to 82 years. Since this study characteristic
could theoretically have led to heterogeneity between
the results of individual studies, we attempted to con-
trol for these differences by including covariates that
described the study design features. Regarding the -
1082 SNP, our analysis showed that IL-10 -1082 GG
is associated with a lower risk of AD only when stud-
ies enrolling patients with a median age higher than 76
years were included. No differences were found when
we analyzed the studies regarding the other two SNPs.
In this regard a possible explanation could be that the
meta-analyses on -819 and -592 SNPs (in contrast to
the -1082 SNP analysis, which includes 14 studies) are
based on a low number of studies, 7 on Caucasian and 2
on Asiatic subjects, and, therefore the subgroup anal-
yses include a number of studies insufficient to give
significant results.
While for the -1082 SNP the biological mechanism,
particularly the association between the genetic poly-
morphism and the cytokine levels, was clearly shown
in several studies, similar evidence is not available for
the -819 and -592 SNPs, unless these polymorphisms
are considered in the context of the entire IL-10 hap-
lotype [8–10]. Indeed, some studies showed a reduced
risk of AD in subjects bearing the supposed high pro-
ducing IL-10 haplotype, -1082G/-819C/-592C [11, 20,
24]. In this regard our analysis suggested a role of
this haplotype in the risk of AD, but due to the small
sample size of the subgroup analysis, including only 4
available studies, we could not show a statistically sig-
nificant result, despite a remarkable pooled summary
OR. In any case, this observation suggests the impor-
tance of the GCC haplotype in the IL-10 production or
in the association with AD and recommend analyzing
the entire haplotype rather than the single SNPs sep-
arately. Indeed, it must be noted that the association
between the GCC haplotype with AD is stronger than
the association of the single SNPs reported in the same
4 studies [11, 15, 20, 24] (GCC versus other genotypes:
OR, 0.61; -1082 GG versus AG+AA: OR: 0.76).
The type of AD diagnosis could also be one of the
factors influencing the results of individual studies.
Only a minority of studies analyze patients with a clini-
cal diagnosis of probable or possible AD confirmed by
imaging (MRI/CT) or by neuropathological examina-
tion. When we analyzed these studies (only 4 out of 15
studies), we showed a significant summary result with
a remarkable pooled OR, suggesting that an important
source of heterogeneity between the results of indi-
vidual studies on AD, regarding not only the IL-10
but every SNPs considered, could be the uncertainty
of the diagnosis based only on the NINCDS-ADRDA
working group criteria.
However, caution must be exercised in interpreting
these results since all these exploratory analyses are
drawn from subgroup analyses.
This retrospective analysis has some limitations that
should be acknowledged. First, one may argue that our
meta-analysis does not have sufficient power to detect
an OR of 0.8 or greater on the relations between IL-10
variants and the risk of AD. It must be emphasized
that almost all studies included in this meta-analysis
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are small or medium sized case-control studies, with
little statistical power to detect the final OR.
Second, in two of the studies included in the
meta-analysis, controls were not in Hardy–Weinberg
equilibrium (HWE) [11, 17]. The sensitivity analy-
sis, excluding these studies, did not alter the pattern
of results in terms of sensitivity, but the association
was not statistically significant, even after the exclu-
sion of the influential study from Ribizzi [25]. Given
the small number of studies available for the analysis,
the loss of statistical significance of the sensitivity anal-
ysis excluding the studies with departure from HWE
may be the result of the sample size reduction. But, it
also means that the results of this meta-analysis can-
not be considered robust, since the exclusion of even
one study can lead to the loss of statistical signifi-
cance.
Another significant limitation of this meta-analysis
is that the results could not be adequately adjusted
by patient characteristics or any other AD established
genetic susceptibility factor, e.g., APOE 4 [2]. Only
an individual patient data meta-analysis could address
this issue and unveil population stratifications pos-
sibly leading to heterogeneity among study results.
This could lead to clearly understanding the role of
the numerous genetic associations [32, 33], many of
which without unequivocal statistical support, which
is, however, not unexpected given the complex mul-
tifactorial nature of AD [2]. Anyway, it is intriguing
that the same SNP thought to be involved in the control
of AD is associated with the control of atherosclero-
sis and favor longevity [10]. So the anti-inflammatory
cytokine IL-10 and, reciprocally, the pro-inflammatory
cytokine IL-6 [34, 35] are playing a crucial role in the
attainment of successful or unsuccessful aging [36].
In summary, the available evidence from the present
meta-analysis, based on the examination of a pooled
total of 2,708 cases and 2,948 healthy controls, is not
sufficient to support a protective effect of IL-10 SNPs
on the risk of AD. Nevertheless, the results of this study
suggest a possible role of -1082 SNP, even in the con-
text of the -1082G/-819C/-592C haplotype, on the risk
of developing AD and validate the need for further
investigations.
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